linjc16/ctgov huggingface dataset:
Shanghai Ovarian Cancer and Family Care Project

Study Overview
=================
Brief Summary
-----------------
Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.

Official Title
-----------------
Shanghai Ovarian Cancer and Family Care Project

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Participant meet the criteria for one of the following conditions: Patients attending the oncology department require differential diagnosis of ovarian cancer. Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc. Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms. Exclusion Criteria: Individuals with evidence of another active cancer. Individuals who have prior bilateral oophorectomy. Individuals who are unwilling or unable to sign the informed consent form.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ambispective patient cohort<br>Patients attending the oncology department require differential diagnosis of ovarian cancer. | |
| High-risk population cohort<br>Family members of ovarian cancer patients; family history of BRCA mutation-related disease; abnormal findings on ovarian cancer screening; history of ovarian disease and other risk factors. | |
| Healthy control cohort<br>Healthy women with normal health examination results. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death due to ovarian cancer | Death due to ovarian cancer determined by independent outcomes committee. | From diagnosis of ovarian cancer until October 31, 2028. |
Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO

Study Overview
=================
Brief Summary
-----------------
Prone position ventilation was used 220 times in 44 out of 68 patients with severe COVID-19 induced ARDS treated with VV-ECMO. PPV treated patients did not benefit from PPV and the incidence of PPV related adverse events was high

Detailed Description
-----------------
Purpose: To describe the use and effects of prone position ventilation (PPV) in patients with COVID-19 induced Adult Respiratory Distress Syndrome (ARDS), treated with Veno-Venous Extracorporeal membrane oxygenation (VV-ECMO). Methods: Nationwide retrospective analysis of all COVID-19 patients in Denmark from March 2020 - December 2021with severe ARDS and need of VV-ECMO treatment. Data on the number of patients treated with PPV, number of PPV-events, timing, the time spent in prone position, physiological response types, adverse events and outcomes are reported.

Official Title
-----------------
Use of Prone Position Ventilation (PPV) in Danish Patients With COVID-19 Induced Severe Adult Respiratory Distress Syndrome (ARDS) Treated With Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

Conditions
-----------------
ARDS, Human, Extracorporeal Membrane Oxygenation, COVID-19 Acute Respiratory Distress Syndrome, Prone Position, Adverse Event

Intervention / Treatment
-----------------
* Other: Prone position ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with COVID-19 induced severe ARDS accepted for and treated with VV-ECMO in Denmark - Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Prone position ventilation|Turning the patient prone for 16 hours|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 90 day mortality | all cause mortality 90 days after ECMO start | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time-to-wean | Time from ECMO start to succesful weaning from ECMO | From start of ECMO treatment to succesful weaning from ECMO | 
| Recruitment Response to prone position ventilation | lung recruitment | from prone position start to prone position end | 
| Oxygenation Response to prone position ventilation | Oxygenation | from prone position start to prone position end | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ARDS, VV-ECMO, Prone position ventilation, Adverse Events
Map of Unwanted Loneliness

Study Overview
=================
Brief Summary
-----------------
Creating a map of the magnitude of the problem and the response of primary care to unwanted loneliness among the elderly, stratifying different needs based on place of residence and proximity to available assistance programs to address this issue, which, due to its scale, calls for collaboration among various institutions, disciplines, and experiences.

Official Title
-----------------
Map of Unwanted Loneliness

Conditions
-----------------
Loneliness

Intervention / Treatment
-----------------
* Other: Exploration of a database


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Population aged 65 or older. Registration of medical records related to unanticipated loneliness. Patients with diagnoses of anxiety disorders (CIE-10 F41.1, F41.2, F41.8, F41.9, F43.2, F45, F48) or insomnia (CIE-10 F51) or affective disorders (CIE-10 F34.1) or somatization (CIE-10 F45.0) or pathological grief (CIE-10 Z63.4) or those referred to mental health or social worker services. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Exploration of a database|extraction of data|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NH | Number of hospitalizations | 21 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NFMV | Number of family medicine visits | 21 months | 
| NPCNV | Number of primary care nursing visits | 21 months | 
| NPSWV | Number of primary care social work visits | 21 months | 
| NFPV | Number of primary care physiotherapy visits | 21 months | 
| NCPHV | Number of primary care home consultations | 21 months | 
| NCEPV | Number of primary care emergency consultations | 21 months | 
| NHD | Number of hospitalization days | 21 months | 
| NTDMGE | Number of total daily medications (general and related to emotional condition) | 21 months | 
| NTEM | Number of total daily medications (related only to emotional condition) | 21 months |
The Impact of Outdoor Sports Practice on the Well-Being of Disabled People

Study Overview
=================
Brief Summary
-----------------
Survey of the members of the French Handisports Federation (FFH) practicing outdoor sports.

Detailed Description
-----------------
This is a national cross-sectional study to investigate the impact of outdoor sports practice on the well-being and self-esteem of people with disabilities. The study is based on a survey of FFH members practicing outdoor sports. The survey will be distributed between October and November 2023 via the federation's internal communication system. Data will be collected on outdoor sports activity, psychological impact and barriers to practice. Analyses will be made between able-bodied and disabled members, between types of disability, and between types of outdoor sport practiced (water, land and air). Analysis will be based on anomysed data and will respect the MR004 methodology.

Official Title
-----------------
The Impact of Outdoor Sports Practice on the Well-Being of Disabled People : a Cross-Sectional Study

Conditions
-----------------
Disability or Chronic Disease Leading to Disablement

Intervention / Treatment
-----------------
* Other: Questionnaire survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being a member of the French Handisport Federation between September 2022 and August 2023 Practicing outdoor sports Exclusion Criteria: Persons who have objected to be contacted by e-mail
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All subjects with impairments<br> | Other: Questionnaire survey<br>* On outdoor sports practice activity, barriers to practice, impacts on well-being.<br>|
| All subjects without impairments<br> | Other: Questionnaire survey<br>* On outdoor sports practice activity, barriers to practice, impacts on well-being.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of my outdoor sports on my well-being | Rating Scale : 1 (low) to 10 (high) | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of my outdoor sports on my self-esteem | Rating Scale : 1 (low) to 10 (high) | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Physical activities, Outdoor sports, Disability
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML

Study Overview
=================
Brief Summary
-----------------
The study is to evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of BC3402 in combination with azacitidine (AZA) in subjects with Myelodysplastic Syndrome (MDS) and Chronic myelomonocytic leukemia (CMML)

Official Title
-----------------
A Phase 1b Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of BC3402 in Combination With Azacitidine in Subjects With Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Conditions
-----------------
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia

Intervention / Treatment
-----------------
* Drug: BC3402
* Drug: Azacitidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: MDS and CMML subjects with higher risk; Age ≥ 18 years old; Eastern Cooperative Oncology Group score of 0 2; Not suitable for or refuse to receive hematopoietic stem cell transplant(HSCT); Subjects should take effective contraceptive measures Must sign the Informed Consent Form (ICF), and be able to follow all study procedures. Exclusion Criteria: Prior exposure to anti-TIM-3 therapy at any time Previous HSCT Live vaccine administered within 4 weeks prior to start of treatment Current use or use within 7 days prior to start of treatment of systemic steroid therapy (> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic steroids are allowed. Other protocol-defined Inclusion/Exclusion may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BC3402+azacitidine<br>Subjects will receive azacitidine and BC3402 in a treatment cycle. | Drug: BC3402<br>* Escalating of BC3402 will be administered IV(intravenous)<br>Drug: Azacitidine<br>* Azacitidine will be administered daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with AEs and SAEs Primary endpoint:Incidence of dose limiting toxiecities(DLTs) and incidence of DLT events within 28 days (first cycle) | To evaluate the safety and tolerability of BC3402 | 2.5 years |
Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy

Study Overview
=================
Brief Summary
-----------------
Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage . New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti_EGFR ,anti_angiogenic and kinase inhibitors .

Detailed Description
-----------------
Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti_EGFR targeted therapy between left colon and rectal cancer

Official Title
-----------------
Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy

Conditions
-----------------
Metastatic Colorectal Adenocarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age above 18 Both sex Performance status zero to one according to ECOG scale system Histo-pathologial diagnosis adenocarcinoma of left colon or rectum. Patients diagnosed with left colon and rectal cancer. Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC. Patients diagnosed with metastatic stage. K-RAS wild type. Exclusion Criteria: Second malignancy Histo-pathological types other than adenocarcinoma. Right colon cancer patients. Patients refused receiving anti_EGFR targeted therapy. Patients with any abnormalities preventing to receive chemotherapy. Early stages of colorectal cancer. K-RAS mutant type.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy | Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment | Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy. | Factors affecting response to targeted therapy | The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EGFR, Targeted therapy ,metastatic colorectal cancer
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

Study Overview
=================
Brief Summary
-----------------
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2023, 22 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma.

Conditions
-----------------
Glioblastoma, Squamous Cell Carcinoma, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Breast Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Acute Leukemia, Pancreatic Cancer, Spindle Cell Sarcoma, Cancer, Tumor, Solid, Tumor, Brain

Intervention / Treatment
-----------------
* Drug: AVM0703
* Drug: Hydrocortisone
* Drug: Proton pump inhibitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AVM0703|small molecule immunomodulatory drug|
|Drug: Hydrocortisone|physiologic circadian glucocorticoid|
|Drug: Proton pump inhibitor|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called cabergoline which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Official Title
-----------------
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial

Conditions
-----------------
Lactation Suppressed, Second Trimester Abortion

Intervention / Treatment
-----------------
* Drug: Cabergoline
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises ages 18 to 50 con provide informed consent in English Exclusion Criteria: Age under 18 or above 50 gestational ages before 16 weeks 0 days or after 20 weeks 0 days unable to provide written consent in English hypertensive disorder uncontrolled hypertension or known hypersensitivity to ergot derivatives History of cardiac valvular disorders history of pulmonary fibrosis documented bipolar schizophrenia documented allergy to medication, including lactose intolerance (placebo pill involves lactose)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cabergoline<br>1mg oral cabergoline administered once after patient's procedure | Drug: Cabergoline<br>* 1mg oral cabergoline given to participants once<br>|
| Placebo Comparator: Placebo<br>1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure | Drug: Placebo<br>* 1 encapsulated placebo tablet given to participants after procedure<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| breast symptoms | Using the bristol breast inventory to assess breast symptoms (engorgement, lactation, etc). | 3 days post procedure and two weeks post procedure |
Non Contrast CT in Acute Appendicitis

Study Overview
=================
Brief Summary
-----------------
To evaluate Diagnostic accuracy of Non-contrast CT in correlation with ultrasound in diagnosis of acute appendicitis in adults

Detailed Description
-----------------
Acute appendicitis is a prevalent cause of abdominal pain, with an estimated lifetime risk of 7 to 9%.[1] Diagnosing appendicitis on CT has a sensitivity and specificity of 87% and 76%, respectively. Classically, diagnosis of acute appendicitis is by identifying an enlarged appendix (greater than 6 mm in diameter) . Some studies suggest using a cut-off value of over 7 mm to improve the prognostic capability of CT. On the other hand, appendicitis is regularly diagnosed using radiology studies. In fact, imaging is often the deciding factor between operative and non-operative management. Though the diagnosis can be clinical following a thorough history and physical, imaging is regularly employed to confirm the diagnosis in question. The most commonly used radiographic study is the CT scan, given its speed, sensitivity, and specificity. US is also relatively useful modality to diagnose acute appendicitis, it has its limitations. Ultrasound is highly operator dependent and tends to work best on individuals with less fat and muscle content in their abdomen (i.e., children). Currently, the negative appendectomy is less than 12% in men but can be up to 33% in women; accurate imaging studies could reduce the number of unnecessary surgeries performed on patients. It is, therefore, essential to know which study will provide the clinician with the most accurate information for their specific clinical scenario.

Official Title
-----------------
Diagnostic Accuracy of Non-Contrast Computed Tomography in Correlation With Ultrasound in Detecting Acute Appendicitis in Adults

Conditions
-----------------
Acute Appendicitis

Intervention / Treatment
-----------------
* Device: CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patient (male or female) with clinical suspicion of acute appendicitis . Exclusion Criteria: pregnant ladies and patients with history of appendectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: CT|NON CONTASR COMPUTED TOMOGRAPHY|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| accuracy of non contrast CT in correlation with ultrasound in acute appendicitis . | Diagnostic Accuracy of Non-Contrast Computed Tomography in Correlation with Ultrasound in Detecting Acute Appendicitis in Adults. | baseline |